Patient preference: weekly injection vs potential monthly depot

KevinCompounds said:

Start from the measurement rather than the conclusion.

I would rather people stopped quoting the 24% as if it were a licensed outcome. It is a phase 2 result in a few hundred participants with no cardiovascular endpoint and no long-term safety data, and this board has a habit of treating pipeline numbers as settled.

Adding the numbers, since they settle part of this. Worth stating the units and the reference range whenever you post a number here. A large fraction of the apparent disagreement in these threads is two people using different units and both being right.

kate.chem said:

I would rather people stopped quoting the 24% as if it were a licensed outcome.

Coming at kate.chem’s question from a different direction. If two explanations both fit, the useful question is which one predicts something the other does not. That is answerable; arguing about which sounds more plausible is not.

That is the short version; the long version is somebody else's post.

One thing that is still open after tammy_FL’s answer:

What the phase 2 dropout pattern implies about how the phase 3 tolerability will read?

Reporting back.

Rereading it with the dropout table open changed my view. I still think it is the most interesting molecule in the pipeline; I no longer think the 24% is the number that will end up on a label.